twoXAR Pharmaceuticals, a company that discovers drugs with AI, announced on Tuesday that it has named Mark Eller, PhD as the senior vice president of Research and Development and Anjali Pandey, PhD as the senior vice president of Nonclinical R&D and Chemistry.

Both Dr Eller and Dr Pandey will report directly to Andrew A Radin, CEO at twoXAR.

Dr Eller is a pharmaceutical industry executive who has 30 years of R&D experience. Prior to joining twoXAR, Dr Eller served as SVP Research & Clinical Development at Jazz Pharmaceuticals. He is an inventor on the patents that offered the original marketing exclusivity for Allegra (fexofenadine), and those that provide the longest-term coverage for Xyrem (sodium oxybate), both products obtaining annual sales of more than USD1.5bn.

The company said that Dr Pandey is a leader in the pharmaceutical industry and has 25 years of experience in all stages of drug discovery and development. Prior to joining twoXAR Pharmaceuticals, Dr Pandey held chief scientific officer positions at BridgeBio Pharma subsidiaries TheRas and Ferro Therapeutics and was senior vice president of Medicinal Chemistry & Chemical Development at Portola Pharmaceuticals where she led discovery and CMC for Bevyxxa (betrixaban) and cerdulatinib. Dr Pandey has worked across antithrombotic, oncology, inflammation, and autoimmune therapeutic areas, is inventor of 60 issued patents, and has published 45 scientific articles.